- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05739136
MYFEMBREE®: A Retrospective Cohort Study Using an Administrative Healthcare Database to Assess Pregnancy Outcomes in Women Treated With Relugolix Combination Therapy
March 6, 2024 updated by: Sumitomo Pharma Switzerland GmbH
This is a retrospective cohort study that will be conducted using secondary de-identified electronic healthcare data (EHD) that originally were collected for the purposes of health insurance billing and/or routine patient care from healthcare providers (HCPs).
The study is designed to evaluate the association between relugolix combination therapy (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) exposure during pregnancy and subsequent fetal and infant outcomes.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
The study will identify pregnant women exposed to relugolix combination therapy during pregnancy from a United States (US) administrative claims database.
The primary outcome measure is major congenital malformations (MCMs) among linked live births.
Secondary outcome measures include spontaneous abortion (SAB), stillbirth, small size for gestational age (SGA), and preterm birth.
Infants of pregnancies with linked live birth outcomes will be followed up to 12 months of age for identification of MCMs.
Anticipated enrollment is 530 live births.
Study Type
Observational
Enrollment (Estimated)
530
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Myovant Medical Monitor Study Director
Study Contact Backup
- Name: Clinical Trials at Myovant
- Phone Number: 650-278-8743
- Email: ClinicalTrials@Myovant.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population will include 2 cohorts: The exposed cohort will include pregnant women with conditions for which relugolix combination therapy is prescribed and who are exposed to relugolix combination therapy at any time during pregnancy.
The unexposed cohort will include pregnant women with conditions for which relugolix combination therapy could be prescribed and who are not exposed to relugolix combination therapy at any time during pregnancy.
Description
Inclusion Criteria:
- Woman ≥ 18 and ≤ 50 years of age at time of conception
- Diagnosis of a condition for which relugolix combination therapy is prescribed (diagnosis captured at any time prior to the estimated date of conception)
Cohort 1
- Exposure to relugolix combination therapy at any time during pregnancy
Cohort 2
- No exposure to relugolix combination therapy at any time after the estimated date of conception (during pregnancy)
Exclusion Criteria:
- Exposure to known teratogens during pregnancy
- < 6 months of continuous healthcare coverage immediately prior to date of conception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Exposed Cohort
Pregnant women with conditions for which relugolix combination therapy is prescribed, who are exposed to relugolix combination therapy at any time during pregnancy
|
Relugolix combination therapy (relugolix 40 mg; estradiol 1 mg; norethindrone 0.5 mg)
Other Names:
|
Unexposed Cohort
Pregnant women with conditions for which relugolix combination therapy could be prescribed, who are not exposed to relugolix combination therapy at any time during pregnancy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major Congenital Malformation (MCM)
Time Frame: Up to 5 years
|
Comparison of rate of MCM between cohorts
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Spontaneous abortion (SAB)
Time Frame: Up to 5 years
|
Comparison of rate of SABs between cohorts
|
Up to 5 years
|
Stillbirth
Time Frame: Up to 5 years
|
Comparison of rate of stillbirths between cohorts
|
Up to 5 years
|
Preterm birth
Time Frame: Up to 5 years
|
Comparison of rate of preterm births between cohorts
|
Up to 5 years
|
Small for gestational age (SGA)
Time Frame: Up to 5 years
|
Comparison of rate of SGA between cohorts
|
Up to 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
January 1, 2025
Primary Completion (Estimated)
May 1, 2027
Study Completion (Estimated)
May 1, 2027
Study Registration Dates
First Submitted
February 13, 2023
First Submitted That Met QC Criteria
February 13, 2023
First Posted (Actual)
February 22, 2023
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 6, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Pregnancy Complications
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Androgen Antagonists
- Estradiol
- Norethindrone
- Norethindrone Acetate
- Relugolix
Other Study ID Numbers
- MVT-601A-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy Complications
-
The Cooper Health SystemRecruitingPregnancy,Neoplastic ComplicationsUnited States
-
Northwestern UniversityTerminatedPregnancy Related | Labor ComplicationUnited States
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...Terminated
-
Jazz PharmaceuticalsRecruitingPregnancy | Pregnancy Complication | Maternal Complications | Birth Outcomes, AdverseUnited States
-
Oslo University HospitalRecruitingPregnancy Related | Labor Complication | Induced; BirthNorway
-
Thomas Jefferson UniversityCompleted
-
University Hospital Center of MartiniqueCompletedLabor Complication | CervixMartinique
-
Washington University School of MedicineUniversity of MichiganRecruiting
-
Egas Moniz - Cooperativa de Ensino Superior, CRLCompleted
-
PerspectumUniversity of Oxford; Fetal Medicine FoundationCompletedPregnancy Complications | Fetal Growth ComplicationsUnited Kingdom
Clinical Trials on Relugolix + Estradiol + Norethindrone Acetate
-
Myovant Sciences GmbHCompletedEndometriosis Related PainUnited States, Spain, Hungary, Argentina, Belgium, Bulgaria, Canada, Czechia, Finland, Poland, Portugal, South Africa, Ukraine
-
Myovant Sciences GmbHCompletedEndometriosis Related PainUnited States, Poland, Australia, Brazil, Chile, Czechia, Georgia, Italy, New Zealand, Romania, Sweden
-
Myovant Sciences GmbHCompletedUterine Fibroid | Heavy Menstrual BleedingUnited States, Belgium, Czechia, South Africa, Chile, Brazil, Hungary, Poland
-
Myovant Sciences GmbHCompletedUterine Fibroid | Heavy Menstrual BleedingUnited States, Italy, Poland, Brazil, South Africa, United Kingdom
-
NorthShore University HealthSystemPfizerNot yet recruiting
-
Myovant Sciences GmbHCompletedUterine Fibroids | Uterine LeiomyomaUnited States, Italy, Poland, Czechia, Hungary, South Africa, Brazil, Chile
-
Teva Pharmaceuticals USACompleted
-
Warner ChilcottCompleted
-
Myovant Sciences GmbHCompletedUterine Fibroid | Heavy Menstrual BleedingUnited States, Italy, Belgium, Czechia, Hungary, Poland, South Africa, Chile, Brazil
-
Teva Pharmaceuticals USACompleted